TY - JOUR T1 - Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study JF - CMAJ Open SP - E605 LP - E614 DO - 10.9778/cmajo.20160008 VL - 4 IS - 4 AU - Alison D. Marshall AU - Sahar Saeed AU - Lisa Barrett AU - Curtis L. Cooper AU - Carla Treloar AU - Julie Bruneau AU - Jordan J. Feld AU - Lesley Gallagher AU - Marina B. Klein AU - Mel Krajden AU - Naglaa H. Shoukry AU - Lynn E. Taylor AU - Jason Grebely AU - the Canadian Network on Hepatitis C (CanHepC) Y1 - 2016/10/14 UR - http://www.cmajopen.ca/content/4/4/E605.abstract N2 - Background: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada.Methods: We reviewed the reimbursement criteria for simeprevir, sofosbuvir, ledipasvir-sofosbuvir and paritaprevir-ritonavir-ombitasvir plus dasabuvir in the 10 provinces and 3 territories. Data were extracted from April 2015 to June 2016. The primary outcomes extracted from health ministerial websites were: 1) minimum fibrosis stage required, 2) drug and alcohol use restrictions, 3) HIV coinfection restrictions and 4) prescriber type restrictions.Results: Overall, 85%-92% of provinces/territories limited access to patients with moderate fibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis stage F2 or greater, or equivalent). There were no drug and alcohol use restrictions; however, several criteria (e.g., active injection drug use) were left to the discretion of the physician. Quebec did not reimburse simeprevir and sofosbuvir for people coinfected with HIV; no restrictions were found in the remaining jurisdictions. Prescriber type was restricted to specialists in up to 42% of provinces/territories.Interpretation: This review of criteria of reimbursement of HCV direct-acting antivirals in Canada showed substantial interjurisdictional heterogeneity. The findings could inform health policy and support the development and adoption of a national HCV strategy. ER -